Correlations between serum syndecan-1 and other variables at diagnosis
| . | Serum Creatinine . | Urine M-Component . | IL-6 Receptor . | ICTP . | β2-Microglobulin . | % Marrow Plasma Cells . | Stage . | Serum M-Component . |
|---|---|---|---|---|---|---|---|---|
| N | 174 | 164 | 173 | 157 | 174 | 173 | 174 | 173 |
| r* | 0.41 | 0.29 | 0.28 | 0.25 | 0.25 | 0.21 | 0.20 | 0.17 |
| P value | <.0001 | <.0001 | <.0001 | .002 | .001 | .005 | .008 | .02 |
| . | Serum Creatinine . | Urine M-Component . | IL-6 Receptor . | ICTP . | β2-Microglobulin . | % Marrow Plasma Cells . | Stage . | Serum M-Component . |
|---|---|---|---|---|---|---|---|---|
| N | 174 | 164 | 173 | 157 | 174 | 173 | 174 | 173 |
| r* | 0.41 | 0.29 | 0.28 | 0.25 | 0.25 | 0.21 | 0.20 | 0.17 |
| P value | <.0001 | <.0001 | <.0001 | .002 | .001 | .005 | .008 | .02 |
Only statistically significant correlations are included. There was no significant correlation between syndecan-1 and pretreatment age, type of serum M-component, radiographic staging of bone destruction, IL-6, CRP, calcium, HGF, alkaline phosphatase, albumin, or osteocalcin.
r indicates correlation coefficient for syndecan-1 and the designated variable.